Clindets® (Clindamycin Phosphate Pledgets) contain clindamycin phosphate, USP at a concentration equivalent to 10 mg clindamycin per milliliter in a vehicle of isopropyl alcohol 52% v/v, propylene glycol and water. Each Clindets® pledget applicator contains approximately 1 mL of Clindamycin Phosphate Topical Solution. Clindamycin Phosphate Topical Solution has a pH range between 4.0 and 7.0.
Clindets are indicated in the treatment of acne vulgaris. In view of the potential for diarrhea, bloody diarrhea and pseudomembranous colitis, the physician should consider whether other agents are more appropriate. (See CONTRAINDICATIONS, WARNINGS, and ADVERSE REACTIONS.)
Media Articles Related to Clindets (Clindamycin Topical)
Acne's Silver Lining: Slower Aging of the Skin?
Source: MedicineNet Acne Specialty [2016.09.30]
Title: Acne's Silver Lining: Slower Aging of the Skin?
Category: Health News
Created: 9/29/2016 12:00:00 AM
Last Editorial Review: 9/30/2016 12:00:00 AM
Hormonal Acne: Causes, Types, and Treatment
Source: Endocrinology News From Medical News Today [2016.09.26]
Acne is sometimes called hormonal acne because of how the skin problem develops in response to hormonal changes. Learn about its treatment and symptoms.
Acne Care Pictures: Skin Care Dos and Don'ts
Source: MedicineNet Acne Specialty [2016.09.12]
Title: Acne Care Pictures: Skin Care Dos and Don'ts
Created: 8/1/2012 12:00:00 AM
Last Editorial Review: 9/12/2016 12:00:00 AM
Acne Treatment Differin Gel Approved for OTC Use
Source: MedicineNet adapalene Specialty [2016.07.12]
Title: Acne Treatment Differin Gel Approved for OTC Use
Category: Health News
Created: 7/11/2016 12:00:00 AM
Last Editorial Review: 7/12/2016 12:00:00 AM
FDA OKs Non-Prescription Use of Acne Drug
Source: MedicineNet adapalene Specialty [2016.07.11]
Title: FDA OKs Non-Prescription Use of Acne Drug
Category: Health News
Created: 7/8/2016 12:00:00 AM
Last Editorial Review: 7/11/2016 12:00:00 AM
Published Studies Related to Clindets (Clindamycin Topical)
Efficacy of clindamycin in reducing pain following tonsillectomy in adults: a
double-blind, randomised trial. 
reducing throat pain after tonsillectomy in adult patients... CONCLUSION: Topical clindamycin was not demonstrated to be more effective than
Topical 4% nicotinamide vs. 1% clindamycin in moderate inflammatory acne
Nicotinamide and clindamycin gels are two popular topical medications for acne
vulgaris... Skin type is a significant factor in choosing
between topical nicotinamide and clindamycin in patients with acne vulgaris.
A randomized, double-blind, placebo-controlled, pilot study to assess the
efficacy and safety of clindamycin 1.2% and tretinoin 0.025% combination gel for
the treatment of acne rosacea over 12 weeks. 
rosacea after 12 weeks of usage... CONCLUSIONS: A combination gel of clindamycin phosphate 1.2% and tretinoin 0.025%
Efficacy and safety of topical nadifloxacin and benzoyl peroxide versus clindamycin and benzoyl peroxide in acne vulgaris: A randomized controlled trial. [2011.11]
BACKGROUND: Topical therapy with comedolytics and antibiotics are often advocated for mild and moderate severity acne vulgaris. Nadifloxacin, a new fluoroquinolone with anti-Propionibacterium acnes activity and additional anti-inflammatory activity, is approved for use in acne. This randomized controlled assessor blind trial compared the clinical effectiveness and safety of eight weeks therapy of nadifloxacin 1% versus clindamycin 1% as add-on therapy to benzoyl peroxide (2.5%) in mild to moderate grade acne... CONCLUSIONS: Topical nadifloxacin, a new fluoroquinolone is effective, tolerable, and safe for mild o moderate facial acne. Its clinical effectiveness is comparable to clindamycin when used as add-on therapy to benzoyl peroxide.
Efficacy of topical combination of benzoyl peroxide 5% and clindamycin 1% for the treatment of progressive macular hypomelanosis: a randomized, doubleblind, placebo-controlled trial. [2011.02]
BACKGROUND: Progressive macular hypomelanosis is a dermatosis without definite etiology. There is no consensus or first-line therapy in the treatment of progressive macular hypomelanosis, and the treatment options used are very little effective. OBJECTIVE: To evaluate the therapeutic efficacy of the topical combination of benzoyl peroxide 5% and clindamycin 1% associated with sun exposure for the treatment of progressive macular hypomelanosis... CONCLUSION: The topical combination of benzoyl peroxide 5% and clindamycin 1% is effective in the treatment of progressive macular hypomelanosis.
Clinical Trials Related to Clindets (Clindamycin Topical)
Adherence to Study Medication Compared to Generic Topical Clindamycin Plus Generic Topical Tretinoin in Subjects With Mild to Moderate Acne Vulgaris [Completed]
The purpose of this research study is to evaluate the effectiveness of two different types
of topical acne medication. This study will help to determine if one combined medication
results in better acne improvement than two separate medications for acne.
Systemic and Topical Treatments for Rash Secondary to Erlotinib in Lung Cancer [Completed]
The purpose of this trial is to determine if rash caused by erlotinib can be successfully
treated and if so to determine the optimal treatment approach.
Hypothesis 1: If the incidence of rash is 50% while on erlotinib, prophylactic monotherapy
with minocycline can prevent occurrence in 50% of these patients.
Hypothesis 2: Treatment of rash is successful in improving rash by at least one Grade in 80%
Hypothesis 3: In patients with untreated rash, the rash will be self-limiting in 25% of
patients, and 65% will be grade 1, 2A, and 2b. Ten percent will be grade 3 requiring
treatment with monotherapy intervention.
Efficacy and Safety of a Preparation Containing an Antibiotic and Anti-Inflammatory Agent in Acne Vulgaris [Completed]
The concept behind our study was to combine an effect of antibiotic and anti-inflammatory
agents for a more efficient acne therapy directed at the factors involved in the
pathophysiology of the disease. For this purpose we evaluated a combination of clindamycin
phosphate and salicylic acid in a non-irritating carrier.